Over the past several decades, mRNA vaccines have evolved from a theoretical concept to a
clinical reality. These vaccines offer several advantages over traditional vaccine techniques …

The clinical development of 4–1BB agonists for cancer immunotherapy has raised
substantial interest during the past decade. The first generation of 4–1BB agonistic …

Abstract B7 homolog 3 (B7-H3; CD276), a tumor-associated antigen and possible immune
checkpoint, is highly expressed in prostate cancer (PCa) and is associated with early …

Twenty-five years ago, we reported that agonist anti-CD137 monoclonal antibodies
eradicated transplanted mouse tumors because of enhanced CD8+ T-cell antitumor …

Abstract Purpose: 4-1BB (CD137) is a costimulatory immune receptor expressed on
activated T cells, activated B cells, NK cells, and tumor-infiltrating lymphocytes, making it a …

CD137 (4-1BB) is a member of the TNFR family that mediates potent T cell costimulatory
signals upon ligation by CD137L or agonist monoclonal antibodies (mAbs). CD137 agonists …

Head and neck cancer (HNC) is the sixth most common cancer type, accounting for
approximately 277,597 deaths worldwide. Recently, the Food and Drug Administration …

T cells play a critical role in antitumor immunity, where T cell activation is regulated by both
inhibitory and costimulatory receptor signaling that fine-tune T cell activity during different …

Biomarkers for cancer immunotherapy are an unmet medical need. The group of Daniela
Thommen at the NKI recently reported on novel methodologies based on short-term cultures …

T cell depletion and functional impairment are characteristics of sepsis. CD137 is a
costimulatory receptor on activated T cells, while soluble CD137 (sCD137) inhibits CD137 …